Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine as novel treatment in irritable bowel syndrome (IBS)
2013-001199-39Phase 2Completed
- Sponsor
- KU Leuven
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of eribulin in Diarrhea-predominant irritable bowel syndrome (IBS-D) and irritable bowel syndrome (IBS), sponsored by KU Leuven. Primary endpoint: Global symptom relief and abdominal pain. Started Sep 2013; status: completed.
02
Drugs
eribulin
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2013-001199-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001199-39.